

# **Open Respiratory Archives**




www.elsevier.es/ora

### Clinical images

## Bilateral Chylothorax and COVID-19: Report Case

Quilotórax bilateral y COVID-19: reporte de caso



- <sup>a</sup> Hospital de la Amistad Peru Korea Santa Rosa II-2, Peru
- <sup>b</sup> Master in Clinical Epidemiology, Peru
- <sup>c</sup> Vicerrectorado de Investigación, Universidad Norbert Wiener, Lima, Peru
- <sup>d</sup> Archbishop Loayza Hospital, Peru




Fig. 1. (1) August: mild pleural effusion and ground glass: 35–40%. (2) Early September: increase in pleural effusion and decrease in ground glass. (3) End of September: similar characteristics. (4) Reconstruction of coronal section of angio tomography without evidence of vascular thrombotic lesions.

Corresponding author.

E-mail address: franco.leon@uwiener.edu.pe (F.E. León-Jiménez).

During 2021, a 66-year-old man was admitted to the emergency room with 2 month of weight loss, cough with bloody sputum, dyspnea and fever. With IgM and IgG reactive to COVID-19 and the chest CT scan shown (Fig. 1), COVID-19 pneumonia with bilateral pleural effusion was diagnosed; he had normal vital signs; at lungs: bibasal egophony. He had 3 negative sputum smears for tuberculosis, and negatives ELISA and nasal swab antigen for HIV and COVID-19, respectively. He received dexamethasone 10 mg/24h for 5 days, subcutaneous enoxaparin and ceftriaxone 2 g/24h for 5 days<sup>1</sup>; 2000 cm<sup>3</sup> of thick pink fluid was drained, suspecting chylothorax: cholesterol: 250 mg/dl and triglycerides: 420 mg/dl, negative adenosine deaminase and Pap Block cell; 2 chest tubes were placed with 1000 cm<sup>3</sup>/day through both tubes. The tomographic evolution can be seen in Fig. 1(1-4). Three days later he passed away.

This is the second report of chylothorax in a patient with a previous infection by COVID-19. Satriano et al. reported chylothorax due to thrombosis in the superior vena cava.<sup>2</sup> The chest tomography in our case did not show thrombi. Turkdogan et al. found a frequency of chylothorax in COVID patients of 3.2%.<sup>3</sup> Neither tuberculosis nor lymphoma were found. Chylothorax is a potential complication of this disease.

#### **Informed consent**

During hospitalization, verbal informed consent was requested from the patient for a potential publication of his case.

#### **Funding**

Self-financed.

#### **Authors' contributions**

FLJ: devised the publication, collected the information, conducted a bibliographic search, prepared the first version, and reviewed and approved the final version.

SRR: collected the information, conducted a bibliographic search, prepared the first version and reviewed and approved the final version.

SCR: reviewed and approved the first version and reviewed and approved the final version.

ADR: collected the information, conducted a bibliographic search, prepared the first version and reviewed and approved the final version.

#### **Conflicts of interest**

FLI and SRR were the patient's treating physicians.

#### References

- Bartoletti M, Azap O, Barac A, Bussini L, Ergonul O, Krause R, et al. ESCMID COVID-19 living guidelines: drug treatment and clinical management. Clin Microbiol Infect. 2022;28:222–38, http://dx.doi.org/10.1016/j.cmi.2021.11.007.
- Satriano F, Scioscia G, Cagnazzo MG, Maci F, Refolo L, Fuso P, et al. Chylothorax found in a patient with COVID-19. Respirol Case Rep. 2022;10:e0836, http://dx.doi.org/10.1002/rcr2.836.
- 3. Türkdoğan F, Coskun A, Türkdoğan KA. Frequency of spontaneous hemothorax, chylothorax, pleural, and pericardial effusion in patients who had thorax tomography during prepandemic and pandemic period. Preprints. 2022, http://dx.doi.org/10.20944/preprints202207.0295.v1.